IGM Biosciences, Inc. – NASDAQ:IGMS

Add to watchlist

$1.28

-5.09

-79.91%

Market closed

Open in about 7 hours

-33.92%

month

-33.92%

quarter

-23.62%

year

Market Cap	383.24M
Enterprise value	343.68M

P/E	-2.01
EV/Sales	239.50
EV/EBITDA	-1.04
Price/Sales	295.29
Price/Book	1.47
PEG ratio	-2.11
EPS	-4.31

Revenue	2.10M
EBITDA	-249.58M
Income	-236.92M
Revenue Q/Q	-4.78%
Revenue Y/Y	32.30%

Profit margin	-23107.39%
Oper. margin	-23633.17%
Gross margin	25.51%
EBIT margin	-23633.17%
EBITDA margin	-11856.96%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

IGM Biosciences Stock Forecast

M Q Y

Last Year

$18.67

Potential upside: 1358.33%

Analysts Price target
Financials & Ratios estimates

IGM Biosciences, Inc. (NASDAQ:IGMS): Profit margin
Jun 2023	448K	-64.42M	-14380.13%
Sep 2023	509K	-61.98M	-12178.59%
Dec 2023	651K	-60.69M	-9323.35%
Mar 2024	497K	-49.81M	-10023.34%

IGM Biosciences, Inc. (NASDAQ:IGMS): Debt to assets
Jun 2023	480658000	222.05M	46.2%
Sep 2023	474350000	220.48M	46.48%
Dec 2023	423411000	220.17M	52%
Mar 2024	376132000	214.87M	57.13%

IGM Biosciences, Inc. (NASDAQ:IGMS): Cash Flow
Jun 2023	-53.10M	-6.32M	69.95M
Sep 2023	-40.12M	19.54M	44.63M
Dec 2023	-48.00M	-14.69M	402K
Mar 2024	-42.41M	8.65M	152K

IGM Biosciences alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

IGM Biosciences, Inc. (NASDAQ:IGMS): Employee count
Aug 2023	280
Sep 2023	289
Oct 2023	289
Nov 2023	289
Dec 2023	290
Jan 2024	290
Feb 2024	290
Mar 2024	224
Apr 2024	224
May 2024	224
Jun 2024	216
Jul 2024	216

IGM Biosciences
Hedge Funds Holdings Q1 2023

14.95% -25.87%

of IGMS is owned by hedge funds

42 -39

hedge funds hold IGMS stock

6.21M -11.76M

shares is hold by hedge funds

IGMS hedge funds holdings changes

IGM Biosciences
Insider Trading

IGM Biosciences, Inc. (NASDAQ:IGMS): Insider trades (number of shares)
Period	Buy	Sel
Jun 2024	0	11452
Jul 2024	0	15132
Sep 2024	0	11288
Dec 2024	0	5018

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Sale	16 Dec 2024	WEBER STEVEN officer: PRINCIPAL ACCOUNTING OFFICER officer: PRINCIPAL ACCOUNTING O..	Common Stock	539	$7.48	$4,032
Sale	16 Dec 2024	DECKER LISA LYNN officer: CHIEF BUSINESS OFFICER officer: CHIEF BUSINESS OFFICER	Common Stock	1,063	$7.48	$7,951
Sale	16 Dec 2024	HARLER MARY BETH director, officer: Chief Executive Officer director, officer: Chief Execut..	Common Stock	1,708	$7.48	$12,776
Sale	16 Dec 2024	TAHIR MISBAH officer: CHIEF FINANCIAL OFFICER officer: CHIEF FINANCIAL OFFICER	Common Stock	1,708	$7.48	$12,776
Sale	13 Sep 2024	WEBER STEVEN officer: PRINCIPAL ACCOUNTING OFFICER officer: PRINCIPAL ACCOUNTING O..	Common Stock	469	$11.54	$5,412
Sale	13 Sep 2024	TAKIMOTO CHRIS H officer: CHIEF MEDICAL OFFICER officer: CHIEF MEDICAL OFFICER	Common Stock	1,487	$11.54	$17,158
Sale	13 Sep 2024	TAHIR MISBAH officer: CHIEF FINANCIAL OFFICER officer: CHIEF FINANCIAL OFFICER	Common Stock	1,487	$11.54	$17,158
Sale	13 Sep 2024	SCHWARZER FRED director, officer..	Common Stock	3,946	$11.54	$45,533
Sale	13 Sep 2024	KEYT BRUCE officer: CHIEF SC..	Common Stock	1,487	$11.54	$17,158
Sale	13 Sep 2024	HARLER MARY BETH officer: Head, Research & Autoimmunity officer: Head, Research & Autoi..	Common Stock	1,487	$11.54	$17,158

IGMS insider trading transactions

Status	Patent	Filling date	Issue date
Application	Application MULTIMERIC SARS-COV-2 BINDING MOLECULES AND USES THEREOF Filling date: 15 Feb 2022 Issue date: 25 Aug 2022	15 Feb 2022	25 Aug 2022
Grant	Grant Utility: Modified human IgM constant regions for modulation of complement-dependent cytolysis effector function Filling date: 6 Apr 2018 Issue date: 2 Aug 2022	6 Apr 2018	2 Aug 2022
Application	Application MULTIMERIC GITR BINDING MOLECULES AND USES THEREOF Filling date: 24 Feb 2022 Issue date: 9 Jun 2022	24 Feb 2022	9 Jun 2022
Application	Application MULTIMERIC OX40 BINDING MOLECULES AND USES THEREOF Filling date: 17 Feb 2022 Issue date: 2 Jun 2022	17 Feb 2022	2 Jun 2022
Application	Application MULTIMERIC CD40 BINDING MOLECULES AND USES THEREOF Filling date: 17 Dec 2021 Issue date: 7 Apr 2022	17 Dec 2021	7 Apr 2022
Application	Application ANTI-GITR ANTIGEN-BINDING DOMAINS AND USES THEREOF Filling date: 6 Feb 2020 Issue date: 7 Apr 2022	6 Feb 2020	7 Apr 2022
Application	Application MULTIMERIC CD137/4-1BB BINDING MOLECULES AND USES THEREOF Filling date: 17 Aug 2021 Issue date: 16 Dec 2021	17 Aug 2021	16 Dec 2021
Application	Application MULTIVALENT IgM- AND IgA-Fc-BASED BINDING MOLECULES Filling date: 23 Oct 2019 Issue date: 9 Dec 2021	23 Oct 2019	9 Dec 2021
Grant	Grant Utility: Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof Filling date: 7 Jan 2020 Issue date: 7 Dec 2021	7 Jan 2020	7 Dec 2021
Application	Application ANTI-PD-L1 ANTIBODIES Filling date: 10 Feb 2021 Issue date: 3 Jun 2021	10 Feb 2021	3 Jun 2021

IGM Biosciences
Earnings Call Transcripts

Quarter	Transcript
Q4 2022 31 Mar 2023	Q4 2022 Earnings Call Transcript
Q4 2020 30 Mar 2021	Q4 2020 Earnings Call Transcript
Q4 2019 27 Mar 2020	Q4 2019 Earnings Call Transcript

IGMS earnings call transcripts

IGM Biosciences
Executives

Insider	Age	Compensation
Mr. Fred M. Schwarzer (1953) Chief Executive Officer, Pres & Director	72	$847,520
Dr. Shinyu Chen M.D., Ph.D. (1969) Consultant	56	$675,250
Dr. Bruce A. Keyt (1953) Chief Scientific Officer	72	$636,330

IGM Biosciences
Latest News

Friday, 8 November 2024
09:00	IGM Biosciences, Inc. (IGMS) Reports Q3 Loss, Tops Revenue Estimates	zacks.com
07:00	IGM Biosciences Announces Third Quarter 2024 Financial Results and Provides Corporate Update	globenewswire.com
Monday, 4 November 2024
07:00	IGM Biosciences to Present at Three Upcoming Investor Conferences	globenewswire.com
Tuesday, 1 October 2024
11:41	IGM Biosciences' stock tumbles as analysts weigh in on pivot plan with dismay	marketwatch.com
11:40	IGM Biosciences' New Found Focus: Pivots From Cancer To Autoimmune Diseases, Names New CEO	benzinga.com
08:00	IGM Biosciences Stock Drops 27% on ‘Pipeline Transformation' to Autoimmune Diseases	barrons.com
07:54	IGM Biosciences, CPI Card And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session	benzinga.com
Monday, 30 September 2024
16:01	IGM Biosciences Announces Strategic Pivot to Focus Exclusively on Autoimmunity	globenewswire.com
Wednesday, 18 September 2024
10:37	IGM Biosciences (IGMS) Surges 11.6%: Is This an Indication of Further Gains?	zacks.com
Tuesday, 10 September 2024
16:05	IGM Biosciences to Present at the Stifel 2024 Virtual Immunology and Inflammation Summit	globenewswire.com
Thursday, 22 August 2024
13:00	All You Need to Know About IGM Biosciences (IGMS) Rating Upgrade to Buy	zacks.com
Wednesday, 14 August 2024
09:00	IGM Biosciences, Inc. (IGMS) Reports Q2 Loss, Lags Revenue Estimates	zacks.com
07:00	IGM Biosciences Announces Second Quarter 2024 Financial Results and Provides Corporate Update	globenewswire.com
Friday, 12 July 2024
10:36	IGM Biosciences (IGMS) Soars 32.7%: Is Further Upside Left in the Stock?	zacks.com
Wednesday, 29 May 2024
07:00	IGM Biosciences to Present at the Jefferies Healthcare Conference	globenewswire.com
Wednesday, 8 May 2024
18:56	IGM Biosciences, Inc. (IGMS) Reports Q1 Loss, Misses Revenue Estimates	Zacks Investment Research
Friday, 3 May 2024
11:01	IGM Biosciences, Inc. (IGMS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?	Zacks Investment Research
Tuesday, 30 April 2024
13:00	IGM Biosciences (IGMS) Upgraded to Buy: What Does It Mean for the Stock?	Zacks Investment Research
Thursday, 7 March 2024
18:46	IGM Biosciences, Inc. (IGMS) Reports Q4 Loss, Lags Revenue Estimates	Zacks Investment Research
Friday, 1 March 2024
10:56	Wall Street Analysts Think IGM Biosciences, Inc. (IGMS) Could Surge 63.1%: Read This Before Placing a Bet	Zacks Investment Research
Wednesday, 14 February 2024
10:56	Wall Street Analysts Believe IGM Biosciences, Inc. (IGMS) Could Rally 35.08%: Here's is How to Trade	Zacks Investment Research
Thursday, 1 February 2024
07:00	IGM Biosciences to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference	GlobeNewsWire
Tuesday, 16 January 2024
09:47	IGM Bio (IGMS) Stock Rallies 142% in 3 Months: Here's Why	Zacks Investment Research
Wednesday, 3 January 2024
07:00	IGM Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference	GlobeNewsWire
Wednesday, 6 December 2023
02:44	Medivir to present at the Carlsquare Equity Research Investor Day	PRNewsWire
Wednesday, 22 November 2023
02:46	Medivir to present at the Redeye Life Science Day	PRNewsWire
Tuesday, 21 November 2023
02:48	Medivir to present at the Erik Penser Bank Company Event	PRNewsWire
Thursday, 16 November 2023
11:16	Does IGM Biosciences, Inc. (IGMS) Have the Potential to Rally 268.31% as Wall Street Analysts Expect?	Zacks Investment Research
Monday, 13 November 2023
03:49	Medivir to present clinical data at ASCO-GI with fostrox + Lenvima in HCC and shares positive response from Type D meeting with FDA	PRNewsWire
Tuesday, 7 November 2023
07:00	IGM Biosciences to Present at Two Upcoming Investor Conferences	GlobeNewsWire

Ideas & Opinions

Seeking Alpha 12 Feb 2024

IGM Biosciences: Imvotamab Data 2nd Half Of 2024 With Other Inflection Points
Seeking Alpha 13 Mar 2023

IGM Biosciences Looks Attractive Before Phase 2 Readout
Seeking Alpha 23 Feb 2022

IGM Biosciences: Interesting Science, Poor Trial Data

Frequently Asked Questions (FAQ)

What's the price of IGM Biosciences stock today?

One share of IGM Biosciences stock can currently be purchased for approximately $1.28.
When is IGM Biosciences's next earnings date?

Unfortunately, IGM Biosciences's (IGMS) next earnings date is currently unknown.
Does IGM Biosciences pay dividends?

No, IGM Biosciences does not pay dividends.
How much money does IGM Biosciences make?

IGM Biosciences has a market capitalization of 383.24M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 99.25% to 2.13M US dollars.
What is IGM Biosciences's stock symbol?

IGM Biosciences, Inc. is traded on the NASDAQ under the ticker symbol "IGMS".
What is IGM Biosciences's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of IGM Biosciences?

Shares of IGM Biosciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are IGM Biosciences's key executives?
IGM Biosciences's management team includes the following people:
- Mr. Fred M. Schwarzer Chief Executive Officer, Pres & Director(age: 72, pay: $847,520)
- Dr. Shinyu Chen M.D., Ph.D. Consultant(age: 56, pay: $675,250)
- Dr. Bruce A. Keyt Chief Scientific Officer(age: 72, pay: $636,330)
How many employees does IGM Biosciences have?

As Jul 2024, IGM Biosciences employs 216 workers, which is 4% less then previous quarter.
When IGM Biosciences went public?

IGM Biosciences, Inc. is publicly traded company for more then 6 years since IPO on 18 Sep 2019.
What is IGM Biosciences's official website?

The official website for IGM Biosciences is igmbio.com.
Where are IGM Biosciences's headquarters?

IGM Biosciences is headquartered at 325 East Middlefield Road, Mountain View, CA.
How can i contact IGM Biosciences?

IGM Biosciences's mailing address is 325 East Middlefield Road, Mountain View, CA and company can be reached via phone at +65 09657873.
What is IGM Biosciences stock forecast & price target?

Based on 6 Wall Street analysts` predicted price targets for IGM Biosciences in the last 12 months, the avarage price target is $18.67. The average price target represents a 1358.33% change from the last price of $1.28.

IGM Biosciences, Inc.

igmbio.com

Exchange:

NASDAQ

Full time employees:

198

Industry:

Biotechnology

Sector:

Healthcare

IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL). It is also developing IGM-8444, an IgM antibody, which is in Phase 1 clinical trials for the treatment of patients with solid cancers; and IGM-7354, an anti-PD-L1 IgM antibody for the treatment of patients with solid and hematologic malignancies; IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of patients with multiple myeloma; and IGM-2537, a bispecific T cell engaging IgM antibody targeting CD123 and CD3 proteins for the treatment of patients with acute myeloid leukemia, myelodysplastic syndromes, and acute lymphoblastic leukemia. It has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.

+65 09657873

325 East Middlefield Road
Mountain View, CA 94043

CIK: 0001496323
ISIN: US4495851085
CUSIP: 449585108